Physician profile
Greg Hites
NPI 1104233907
$6,559.37
in general payments reported to CMS, 2019-2025
24 companies · $852 in 2025
The $852 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,732 · 2022: $1,240 · 2023: $1,523 · 2024: $1,213 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,034 · Travel and Lodging: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,034.31 |
| Travel and Lodging | $552.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,927.35 | 2021-2025 | Eterna, Proclaim |
| Collegium Pharmaceutical, INC. | $1,291.54 | 2021-2025 | Xtampza, Belbuca |
| Medtronic, INC. | $992.06 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Nalu Medical, INC. | $603.14 | 2023 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.87 | 2021-2025 | Relistor |
| Valinor Pharma, LLC | $192.40 | 2023-2024 | Movantik |
| Scilex Pharmaceuticals INC. | $161.43 | 2021-2023 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $151.03 | 2023 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $119.51 | 2025 | Fanapt |
| Virtus Pharmaceuticals LLC | $116.74 | 2021-2025 | Levorphanol Tartrate |
| Almatica Pharma LLC | $109.66 | 2021-2023 | Gralise, Citalopram, Sertraline Hcl |
| Biodelivery Sciences International, INC. | $82.27 | 2021 | |
| Redhill Biopharma INC. | $48.94 | 2021-2022 | |
| Protega Pharmaceutials INC | $45.11 | 2023 | Roxybond |
| Boston Scientific Corporation | $44.32 | 2023-2024 | Wavewriter Alpha Prime 16, Intracept |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $39.51 | 2025 | Tonmya |
| Pfizer INC. | $36.63 | 2021 | |
| Horizon Therapeutics Plc | $33.07 | 2021-2023 | Krystexxa |
| Arbor Pharmaceuticals, INC. | $32.71 | 2021 | |
| Grt US Holding, INC. | $24.05 | 2021 | |
| Idorsia Pharmaceuticals US INC | $23.48 | 2024 | Quviviq |
| Indivior INC. | $18.60 | 2025 | Sublocade |
| Vertex Pharmaceuticals Incorporated | $18.45 | 2025 | |
| Relievant Medsystems, INC. | $12.50 | 2023 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Hites listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.